Clinical Trial4 Jun 2026, 10:55 am
Suven Life Sciences Masupirdine Phase 3 Trial Continues Unchanged
AI Summary
Suven Life Sciences announced positive outcomes from an independent Data and Safety Monitoring Board (DSMB) review and a pre-specified Interim Analysis of its ongoing global Phase 3 study for Masupirdine (SUVN-502) in Alzheimer's Disease agitation. The DSMB recommended the trial continue as planned with no modifications, identifying no safety concerns. An interim analysis also supported continuing without increasing the sample size. Enrollment is at 88%, with completion expected by September 2026, and top-line results anticipated in Q2-2027.
Key Highlights
- DSMB recommends Phase 3 trial for Masupirdine continue unchanged.
- No safety concerns identified in interim analysis.
- Enrollment at 88%, expected completion by September 2026.
- Top-line results anticipated in Q2-2027.
Price Impact
More from SUVEN